Lipoprotein glycation in atherogenesis

Nahla Younis; Nahla N. Younis; Handrean Soran; Reena Sharma; Valentine Charlton-Menys; Paul N. Durrington

doi:10.2217/clp.09.61

Lipoprotein glycation in atherogenesis

Nahla Younis, Nahla N. Younis, Handrean Soran, Reena Sharma, Valentine Charlton-Menys, Paul N. Durrington

Research output: Contribution to journal › Article › peer-review

Abstract

There has been increasing interest in investigating the role of glycation as an atherogenic modification of lipoproteins; especially after the failure of antioxidant therapy to suppress the incidence of atherogenic cardiovascular diseases in high-risk individuals. Glycation of lipoproteins impairs their function. In the case of LDL, it also leads to rapid scavenger-receptor uptake by monocyte/macrophages. Glycation also diminishes the antiatherogenic properties of HDL. The concentration of circulating glycated LDL, even in nondiabetics, is higher than that of oxidatively modified LDL. Glycated small dense LDL is significantly higher in nondiabetic individuals as well as in Type 2 diabetic patients. Lowering the level of small dense LDL by using statins lowers glycated LDL in Type 2 diabetic patients. This may be one of the reasons for their effect in decreasing cardiovascular risk in these patients. Treatments that prevent glycation of lipoproteins may prevent atherosclerosis and other diabetic complications. © 2009 Future Medicine Ltd.

Original language	English
Pages (from-to)	781-790
Number of pages	9
Journal	Clinical Lipidology
Volume	4
Issue number	6
DOIs	https://doi.org/10.2217/clp.09.61
Publication status	Published - 2009

Keywords

Antiatherogenic lipoprotein
Atherogenic lipoprotein
Glycation
Small dense LDL
Statin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/clp.09.61

Cite this

@article{b797f13501684eb9883fce5aa610330f,

title = "Lipoprotein glycation in atherogenesis",

abstract = "There has been increasing interest in investigating the role of glycation as an atherogenic modification of lipoproteins; especially after the failure of antioxidant therapy to suppress the incidence of atherogenic cardiovascular diseases in high-risk individuals. Glycation of lipoproteins impairs their function. In the case of LDL, it also leads to rapid scavenger-receptor uptake by monocyte/macrophages. Glycation also diminishes the antiatherogenic properties of HDL. The concentration of circulating glycated LDL, even in nondiabetics, is higher than that of oxidatively modified LDL. Glycated small dense LDL is significantly higher in nondiabetic individuals as well as in Type 2 diabetic patients. Lowering the level of small dense LDL by using statins lowers glycated LDL in Type 2 diabetic patients. This may be one of the reasons for their effect in decreasing cardiovascular risk in these patients. Treatments that prevent glycation of lipoproteins may prevent atherosclerosis and other diabetic complications. {\textcopyright} 2009 Future Medicine Ltd.",

keywords = "Antiatherogenic lipoprotein, Atherogenic lipoprotein, Glycation, Small dense LDL, Statin",

author = "Nahla Younis and Younis, {Nahla N.} and Handrean Soran and Reena Sharma and Valentine Charlton-Menys and Durrington, {Paul N.}",

year = "2009",

doi = "10.2217/clp.09.61",

language = "English",

volume = "4",

pages = "781--790",

journal = "Clinical Lipidology",

issn = "1746-0875",

publisher = "Taylor & Francis",

number = "6",

}

TY - JOUR

T1 - Lipoprotein glycation in atherogenesis

AU - Younis, Nahla

AU - Younis, Nahla N.

AU - Soran, Handrean

AU - Sharma, Reena

AU - Charlton-Menys, Valentine

AU - Durrington, Paul N.

PY - 2009

Y1 - 2009

N2 - There has been increasing interest in investigating the role of glycation as an atherogenic modification of lipoproteins; especially after the failure of antioxidant therapy to suppress the incidence of atherogenic cardiovascular diseases in high-risk individuals. Glycation of lipoproteins impairs their function. In the case of LDL, it also leads to rapid scavenger-receptor uptake by monocyte/macrophages. Glycation also diminishes the antiatherogenic properties of HDL. The concentration of circulating glycated LDL, even in nondiabetics, is higher than that of oxidatively modified LDL. Glycated small dense LDL is significantly higher in nondiabetic individuals as well as in Type 2 diabetic patients. Lowering the level of small dense LDL by using statins lowers glycated LDL in Type 2 diabetic patients. This may be one of the reasons for their effect in decreasing cardiovascular risk in these patients. Treatments that prevent glycation of lipoproteins may prevent atherosclerosis and other diabetic complications. © 2009 Future Medicine Ltd.

AB - There has been increasing interest in investigating the role of glycation as an atherogenic modification of lipoproteins; especially after the failure of antioxidant therapy to suppress the incidence of atherogenic cardiovascular diseases in high-risk individuals. Glycation of lipoproteins impairs their function. In the case of LDL, it also leads to rapid scavenger-receptor uptake by monocyte/macrophages. Glycation also diminishes the antiatherogenic properties of HDL. The concentration of circulating glycated LDL, even in nondiabetics, is higher than that of oxidatively modified LDL. Glycated small dense LDL is significantly higher in nondiabetic individuals as well as in Type 2 diabetic patients. Lowering the level of small dense LDL by using statins lowers glycated LDL in Type 2 diabetic patients. This may be one of the reasons for their effect in decreasing cardiovascular risk in these patients. Treatments that prevent glycation of lipoproteins may prevent atherosclerosis and other diabetic complications. © 2009 Future Medicine Ltd.

KW - Antiatherogenic lipoprotein

KW - Atherogenic lipoprotein

KW - Glycation

KW - Small dense LDL

KW - Statin

U2 - 10.2217/clp.09.61

DO - 10.2217/clp.09.61

M3 - Article

SN - 1746-0875

VL - 4

SP - 781

EP - 790

JO - Clinical Lipidology

JF - Clinical Lipidology

IS - 6

ER -

Lipoprotein glycation in atherogenesis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this